Number of dialysis & transplant units figure 10.1

Slides:

Advertisements

Similar presentations

ESRD Registry Committee, Korean Society of Nephrology*

Advertisements

Treated ESRD Incidence Rates for Selected Countries, New ESRD Patients/Million Pop. Year of ESRD Incidence USA (All) JPN* USA (White) CAN FRA NL.

TRT Registry Data 2004 TRT Registry Subcommittee Nephrology Society of Thailand.

UKRR Annual Informatics Meeting, September 2013 Highlights from the 15 th Annual Report Rishi Pruthi Research Fellow UK Renal Registry.

Number of Dialysis and Transplant Units by Year, Number of Units Total Dialysis Only Transplant USRDS 1999 XI-1 Year.

CHRONIC KIDNEY DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.

UK Renal Registry 17th Annual Report Figure 2.1. Prevalence rates per million population by age group and UK country on 31/12/2013.

UK Renal Registry 17th Annual Report Figure 1.1. RRT incidence rates in the countries of the UK 1990–2013.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 8: Pediatric ESRD.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 6: Mortality.

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 14: End-of-life Care for Patients with End-Stage Renal Disease:

2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 10: Dialysis Providers.

USRDS 1999 Point Prevalence Counts by Modality, Data Source, and Year, Count (1000s) Year Center Hemo Functioning Transplant PD Home Hemo Facility.

CHAPTER 2 DIALYSIS IN MALAYSIA Goh Bak Leong Lim Yam Ngo Ong Loke Meng Ghazali Ahmad Lee Day Guat Source: 20 th MDTR Report 2012, NRR.

USRDS USRDS 2002 adr Period prevalent ESRD patient, deaths, & ESRD expenditures figure 12.1.

USRDS 2000 ADR USRDS Hepatitis B vaccine & antibody among patients & unit staff figure 9.1, dialysis patients, 1997, by network.

USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.

USRDS 2000 ADR USRDS Cadaveric donations by gender & race figure 7.1, patients aged

2016 Annual Data Report, Vol 2, ESRD, Ch 13

2016 Annual Data Report, Vol 2, ESRD, Ch 5

2016 Annual Data Report, Vol 2, ESRD, Ch 6

Michael Allon, Michelle L. Robbin Kidney International

Figure 1.1 Identification of new patients in freestanding dialysis facilities Dialysis patients, 2013 Peer Report Dialysis Care & Outcomes in the U.S.,

Figure 10.1 Dialysis unit counts, by unit affiliation, 2011–2014

First-year death rates by modality figure 8

Percent of patients receiving influenza vaccinations figure 5

Odd ratio of developing kidney failure figure 1

Patient populations by study group figure 10

2017 Annual Data Report Healthy People 2020.

Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization

Chapter 12: End-of-life Care for Patients with ESRD:

UK Renal Registry 16th Annual Report

December 31st point prevalent counts by modality figure 3.1

2016 Annual Data Report, Vol 2, ESRD, Ch 4

Hospital admissions per patient, by modality figure 5

2016 Annual Data Report, Vol 2, ESRD, Ch 14

Volume 2: End-Stage Renal Disease

CHAPTER 5 Paediatric Renal Replacement Therapy

Hemoglobin, EPO, & Iron dose figure 4

Figure 1.17 of the 2016 US Renal Data System Annual Data Report, Volume 2, chapter 1 showing the trends in the number of patients with incident ESRD (in.

Marlies Noordzij, Kitty J. Jager Kidney International

2018 Annual Data Report Volume 3: Healthy People 2020

Volume 56, Pages S62-S66 (November 1999)

Volume 64, Pages S3-S12 (December 2003)

CHAPTER 1 All Renal Replacement Therapy In Malaysia

Chapter 12: End-of-life Care for Patients with ESRD:

The risk of hospitalization and modality failure with home dialysis

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective J. Michael Lazarus, MD, Raymond M. Hakim,

Incident diabetes in clinical trials of antihypertensive drugs

Need for better diabetes treatment for improved renal outcome

Volume 65, Issue 4, Pages (April 2004)

UK Renal Registry 14th Annual Report

New ESRD Patients and Main Sources

Cause Specific Death Rates for All Dialysis Patients

UK Renal Registry 16th Annual Report

Volume 54, Issue 2, Pages (August 1998)

Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study Eric D.

Hypothetically predicted yearly generation of liquid waste from germicides used for dialyzer reprocessing in the United States. Hypothetically predicted.

Peter A. McCullough, MD, MPH, Christopher T. Chan, MD, Eric D

Figure 4. Characteristics of U. S. Hospitals, 2004

Lynda Anne Szczech, Ira L. Lazar Kidney International

Antonio Santoro, Elena Mancini Kidney International

Worldwide incidence of ESRD figure 12.1, per million population

Douglas E. Schaubel, Howard I. Morrison, Stanley S.A. Fenton

Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance1 William M.

Changes to the End-Stage Renal Disease Quality Incentive Program

Volume 58, Issue 2, Pages (August 2000)

Stephen Pastan, J. Michael Soucie, William M. McClellan

Maristela Böhlke, PhD American Journal of Kidney Diseases

Per dialysis treatment funding and facility/network staff ratio by ESRD Network. Per dialysis treatment funding and facility/network staff ratio by ESRD.

Presentation transcript:

Number of dialysis & transplant units figure 10.1 USRDS

Growth in number of units & patients, 1994 to 1998 figure 10 Growth in number of units & patients, 1994 to 1998 figure 10.2, by network USRDS

Growth (%) in number of units, 1994 to 1998 figure 10.3, by state Percent growth USRDS

Growth (%) in number of dialysis patients, 1994 to 1998 figure 10 Growth (%) in number of dialysis patients, 1994 to 1998 figure 10.4, by state Percent growth USRDS

Distribution of patients by unit type figure 10.5 USRDS

Hemodialysis patients per station figure 10.6, by network USRDS

In-center hemodialysis treatments figure 10.7, by network USRDS

Units per 100,000 population figure 10.8, 1998, by HSA USRDS

Patient-to-staff ratios figure 10.9, by network USRDS

Patient-to-staff ratios figure 10.10, 1997, by HSA USRDS

Distribution of for-profit & non-profit units figure 10.11, by network 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 10 USRDS

Location of for-profit & non-profit units figure 10.12, 1994 USRDS

Location of for-profit & non-profit units figure 10.13, 1998 USRDS

Distribution of freestanding & hospital-based units figure 10 Distribution of freestanding & hospital-based units figure 10.14, by network 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 10 USRDS

Location of freestanding & hospital-based units figure 10.15, 1994 USRDS

Location of freestanding & hospital-based units figure 10.16, 1998 USRDS

Distribution of chain-affiliated & independent units figure 10 Distribution of chain-affiliated & independent units figure 10.17, by network 9 11 12 13 14 15 16 17 18 10 1 2 3 4 5 6 7 8 USRDS

Location of chain-affiliated & independent units figure 10.18, 1994 USRDS

Location of chain-affiliated & independent units figure 10.19, 1998 USRDS

Distribution of conventional & high-efficiency/high-flux units figure 10.20, by network 6 7 8 9 11 12 13 14 15 16 17 18 10 1 2 3 4 5 USRDS

Location of conventional & high-efficiency/high-flux units figure 10 USRDS

Location of conventional & high-efficiency/high-flux units figure 10 USRDS

Units using polysulfone figure 10.23, 1997 USRDS

Units using cellulose acetate figure 10.24, 1997 USRDS

Units using cuprophane figure 10.25, 1997 USRDS

Units using regenerated cellulose figure 10.26, 1997 USRDS

Membrane type by network figure 10.27, 1997 USRDS

Membrane use nationwide figure 10.28 USRDS

Pyrogen reactions figure 10.29, by membrane type USRDS

Pyrogen reactions figure 10.30, by germicide & reuse practice USRDS

Units practicing dialyzer reuse figure 10.31 USRDS

Location of units by reuse practice figure 10.32, 1997 USRDS

Reuse germicide use figure 10.33 USRDS

Location of units by germicide use figure 10.34, 1997 USRDS

Reuse practices & incidence of HbsAg in hemodialysis patients & staff figure 10.35 USRDS